Welcome to our dedicated page for Theratechnologies news (Ticker: THTX), a resource for investors and traders seeking the latest updates and insights on Theratechnologies stock.
Theratechnologies Inc (NASDAQ: THTX) is a specialty biopharmaceutical company advancing therapies for HIV complications and oncology conditions. This news hub provides investors and medical professionals with essential updates on clinical developments, regulatory milestones, and strategic initiatives.
Access timely information about FDA-approved HIV treatments like EGRIFTA for lipodystrophy and Trogarzo for multidrug-resistant infections, alongside emerging oncology candidates targeting aggressive cancers. Our curated news collection includes earnings reports, partnership announcements, and research breakthroughs.
Key updates cover three focus areas: commercialized HIV therapies, pipeline progress in oncology, and operational developments across North American/European markets. Content types include clinical trial results, regulatory filings, and executive commentary.
Bookmark this page for structured access to Theratechnologies' latest advancements in niche biopharmaceutical solutions. Verify information directly through company filings and press releases for informed decision-making.
Theratechnologies (NASDAQ: THTX) announced that Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer, will speak at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 4:30 p.m. ET. A live webcast of his presentation will be accessible on the company’s investor relations website and archived for 90 days. Theratechnologies focuses on developing innovative therapies to meet unmet medical needs. For more information, visit theratech.com.
Theratechnologies (TSX: TH, NASDAQ: THTX) announced it will report its third quarter financial results for fiscal 2021 on October 13, 2021. The report will cover the period ending August 31, 2021. A conference call will take place on the same day at 8:30 a.m. ET, hosted by Paul Lévesque, for discussing results and business updates. The call can be accessed through various means including a toll-free number and a webcast. An audio replay will be available the same day through specific dialing options until October 20, 2021.
Theratechnologies announced results from the TMB-302 study indicating no difference in pharmacokinetics between Trogarzo® IV Push and IV Infusion methods. The study, conducted by TaiMed Biologics, showed consistent and statistically significant outcomes, with no serious adverse events reported. An sBLA is planned to be filed with the FDA in Q4 2021. The IV Push method offers advantages such as a rapid infusion time and increased patient compliance, with plans for an intramuscular administration also under evaluation.
Theratechnologies (NASDAQ: THTX) announced that CEO Paul Levesque will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021, at 10:00 a.m. ET. A live webcast of the event will be available on the company’s investor relations website, with an archive accessible for 90 days post-event.
Theratechnologies focuses on developing innovative therapies to meet unmet medical needs. More details can be found on their website.
Theratechnologies (THTX) has published significant preclinical data on TH1902 for treating sortilin-positive triple negative breast cancer (TNBC) in the journal Cancer Science. This research indicates the in vivo efficacy and safety of TH1902, a peptide-drug conjugate (PDC) aiming to improve targeted cancer therapy. The FDA has granted fast track designation to TH1902, which is undergoing Phase 1 trials. The study highlights SORT1 expression as a potential biomarker, reinforcing the promise of TH1902 in addressing unmet needs in cancer treatment.
Theratechnologies (TSX: TH, NASDAQ: THTX), a biopharmaceutical company, announced that its President and CEO, Paul Levesque, will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 2:00 p.m. ET. Investors can access a live webcast through the investor relations section of the company's website, with an archive available for 90 days post-event.
The company focuses on developing innovative therapies to address unmet medical needs.
Theratechnologies (THTX) reported Q2 2021 revenues of $17.8 million, a 4% increase from $17.2 million in Q2 2020. EGRIFTA® net sales rose 12% to $10.3 million, while Trogarzo® net sales fell 6% to $7.4 million. The company announced complete discussions with the FDA and EMA on its upcoming Phase 3 trial for tesamorelin targeting NASH, though costs for this trial are expected to be higher than previously estimated. A search for a partnership to support this program's launch has begun. The net loss for the quarter was $6.4 million, or $(0.07) per share.
MONTREAL, June 30, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (THTX) plans to release its financial results for Q2 fiscal 2021, ending May 31, 2021, on July 15, 2021. A conference call will be held at 8:30 a.m. ET to discuss these results, hosted by CEO Paul Lévesque. Interested parties can access the call at 1-844-400-1697 or via webcast. A replay will be available the same day and until July 22, 2021. Theratechnologies focuses on innovative therapies addressing unmet medical needs.
Theratechnologies (THTX) has appointed Frank Holler as an independent member of its Board of Directors, enhancing the board's expertise in capital markets and biotechnology. Holler, who has a strong background in the biotech industry and has led successful companies, is expected to contribute significantly as Theratechnologies advances its global commercial business and clinical pipeline. The company is progressing with TH1902, a Phase 1 clinical trial for solid tumors, and developing tesamorelin for NASH treatment.
